Watch PTHS. Know when insiders buy.
One email the day a filing lands. Free.
PTHS
Pelthos Therapeutics Inc.
7.44
−0.59 −7.35%
USD · close Nov 13
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
40
WATCH · insiders 48, shorts 31
Insiders, 90 days
−$45K
net selling · 0 buys, 3 sells
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $57MP/E —DIV YIELD —FCF YIELD —REV TTM $43.3MNET INCOME −$86.4MNET CASH —52W 7.44 – 33.61SEC XBRL · TTM TO Invalid Date
Who holds it
None of the 15 tracked funds disclose PTHS in their latest 13F. The funds we follow.
13F filings cover US-listed holdings and arrive up to 45 days after quarter end, so positions may have changed since.
Stakes of 5% or more
3i, LP and 2 related9.9%
Ligand Pharmaceuticals Incorporated49.9%
“Item 4 of the Schedule 13D is hereby supplemented as follows: The Merger Agreement. On October 30, 2026, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, Credit Card Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the…”
A 13D means the holder crossed 5% with intent beyond passive ownership and had to state a purpose; a 13G is the passive version. Every new 13D on tracked companies.